<DOC>
	<DOCNO>NCT02418962</DOCNO>
	<brief_summary>This single center , randomize , placebo-controlled , double-blind trial ass safety immunogenicity PfSPZ Vaccine administer direct venous inoculation ( DVI ) . The study conduct Baney District , Bioko Island , Equatorial Guinea ( EG ) , establish whether three dos higher regimen - three dose 2.7x10^5 PfSPZ PfSPZ Vaccine administer 8 week interval - well-tolerated efficacious malaria expose African adult five dose regimen . Specifically , trial address follow objective : three dose regimen : 1 . Safe well tolerate Equatoguinean ( EG ) adult . 2 . As immunogenic EG adult five-dose regimen 1.35x10^5 PfSPZ Tanzanian U.S. adult three- , four- five-dose regimen 2.7x10^5 PfSPZ test Tanzanian , Malian U.S. adult . In addition , exploratory objective , volunteer EG trial follow longitudinally measure incidence malaria initial six month follow immunization , provide preliminary assessment efficacy .</brief_summary>
	<brief_title>Safety Immunogenicity Direct Venous Inoculation Radiation-attenuated PfSPZ Vaccine Equatoguinean Adults</brief_title>
	<detailed_description>This single center , Phase 1 , randomize , double-blind , placebo-controlled trial . Thirty-three healthy male volunteer , age 18 35 year recruit three group . The first group comprise 3 volunteer vaccinate first rest demonstration safety . The safety volunteer receive 2 escalate dos PfSPZ vaccine two week interval , 1.35x10^5 2.7x10^5 PfSPZ . The second group 14 - 20 volunteer receive three vaccination 2.7x10^5 PfSPZ give 0 , 8 16 week ( Tanzania trial , volunteer receive five dose regimen 0 , 4 , 8 , 12 18 week ) . The third group 7 - 10 volunteer act control group group 2 receive three injection normal saline 0 , 8 16 week respectively . Volunteers group 2 3 injected Safety Monitoring Committee ( SMC ) provide clearance base result sentinel 3 volunteer ( group 1 ) . For group 2 3 , five volunteer vaccinate first dose remain volunteer vaccinated subsequent day . The control volunteer help good ass occurrence adverse event compare background disease pattern occur tropical area . The decision dose escalate group 1 immunize large number volunteer group 2 Bioko make full knowledge safety data generate ongoing trial PfSPZ Vaccine test .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy literate male age 18 35 year Good health status base history clinical examination . Long term ( least two year ) permanent residence city Baney community Rebola , Bioko Island , Equatorial Guinea Free malaria parasitaemia blood smear screen Not suffer chronic illness include HIV/AIDS . Able willing come complete one year follow . Answered correctly 10 10 question demonstrate understand study study procedure . Written informed consent . Volunteer agree inform study doctor agree release medical information concern contraindication participation study . Living third party contact study team , alteration consciousness first six month study . Willingness attend study clinician take necessary medication prescribe study period . Availability mobile phone 24 hour whole study period . Agreement participate another study study period . Agreement donate blood study period . Willingness attend study visit . Willingness undergo HIV , hepatitis B hepatitis C test . Plans travel outside Bioko , Equatorial Guinea first nine month study . Previous receipt investigational malaria vaccine participation malaria drug study . History arrhythmias prolong QTinterval cardiac disease . History drug alcohol abuse interfere normal social function . A history psychiatric disease . The use chronic immunosuppressive drug , antibiotic , immune modifying drug within three month study onset ( inhaled topical corticosteroid allow ) study period . Symptoms , physical sign laboratory value suggestive systemic disorder include renal , hepatic , blood , cardiovascular , pulmonary , skin , immunodeficiency , psychiatric , condition could interfere interpretation study result compromise health volunteer . History diabetes mellitus cancer . An estimate , ten year risk fatal cardiovascular disease â‰¥5 % , estimate Systematic Coronary Risk Evaluation ( SCORE ) system . Clinically significant abnormality electrocardiogram ( ECG ) screening . Body Mass Index ( BMI ) 18 30 kg/m2 . Any clinically significant deviation normal range biochemistry hematology blood test urine analysis electrolyte . Positive HIV , hepatitis B virus hepatitis C virus test . Participation clinical study within 30 day prior onset study study period . Volunteers unable closely follow social , geographic psychological reason . Study team employee immediate family relative . Any confirm suspected immunosuppressive immunodeficient condition , include asplenia . Risk factor clinically active tuberculosis + positive tuberculin skin test ( TST )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>PfSPZ Vaccine</keyword>
</DOC>